Cargando…

Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway

The ‘2-week wait’ scheme for referral of patients with cancer to secondary care coincided with the introduction of Department of Health (DoH) Guidelines on referral of patients with suspected lung cancer. The aim of this study was to examine the impact of this process on the urgent referral pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, N R, Le Jeune, I, Baldwin, D R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361660/
https://www.ncbi.nlm.nih.gov/pubmed/16189521
http://dx.doi.org/10.1038/sj.bjc.6602798
_version_ 1782153268097449984
author Lewis, N R
Le Jeune, I
Baldwin, D R
author_facet Lewis, N R
Le Jeune, I
Baldwin, D R
author_sort Lewis, N R
collection PubMed
description The ‘2-week wait’ scheme for referral of patients with cancer to secondary care coincided with the introduction of Department of Health (DoH) Guidelines on referral of patients with suspected lung cancer. The aim of this study was to examine the impact of this process on the urgent referral pathway for lung cancer. Medical records of all patients referred with suspected lung cancer were reviewed for the year prior to introduction of the 2-week wait and DoH guidelines and for the subsequent 24 months. A total of 1044 patients were referred, of which 650 (62%) were found to have malignancy. In the first and second years of the 2-week wait scheme, only 57 and 58% were referred via the scheme. Department of Health guidelines were followed in all but a small number. Median wait time increased from 7 to 9 days. The proportion of all urgent referrals seen within 2 weeks fell from 84 to 71%. The proportion of non-2-week wait urgent referrals being seen within 2 weeks was only 75.5% in the first year of the scheme and fell further to 60.9% in the second year. The absolute number of referrals rose and the proportion having cancer fell from 78% before the scheme to 46% in the second year. During this time, there was no change in stage at presentation. Symptoms were not helpful in discriminating benign from malignant disease and haemoptysis was actually more common in the benign group. However, over 50% of patients in the benign group were appropriate to be seen in secondary care. The 2-week wait scheme has so far failed to reduced waiting times for lung cancer. The findings of this study suggest that this is partly due to continued usage of urgent referral routes outside the 2-week wait scheme and secondly due to a large increase in referrals, probably generated by the introduction of the DoH guidelines. Some adjustment to the guidelines may be appropriate to reflect more emphasis on the early performance of a chest X-ray and the use of direct access to other imaging modalities such as CT. Patients referred outside the 2-week wait are disadvantaged and thus practitioners would be wise to refer all their patients through the 2-week wait system.
format Text
id pubmed-2361660
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616602009-09-10 Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway Lewis, N R Le Jeune, I Baldwin, D R Br J Cancer Clinical Study The ‘2-week wait’ scheme for referral of patients with cancer to secondary care coincided with the introduction of Department of Health (DoH) Guidelines on referral of patients with suspected lung cancer. The aim of this study was to examine the impact of this process on the urgent referral pathway for lung cancer. Medical records of all patients referred with suspected lung cancer were reviewed for the year prior to introduction of the 2-week wait and DoH guidelines and for the subsequent 24 months. A total of 1044 patients were referred, of which 650 (62%) were found to have malignancy. In the first and second years of the 2-week wait scheme, only 57 and 58% were referred via the scheme. Department of Health guidelines were followed in all but a small number. Median wait time increased from 7 to 9 days. The proportion of all urgent referrals seen within 2 weeks fell from 84 to 71%. The proportion of non-2-week wait urgent referrals being seen within 2 weeks was only 75.5% in the first year of the scheme and fell further to 60.9% in the second year. The absolute number of referrals rose and the proportion having cancer fell from 78% before the scheme to 46% in the second year. During this time, there was no change in stage at presentation. Symptoms were not helpful in discriminating benign from malignant disease and haemoptysis was actually more common in the benign group. However, over 50% of patients in the benign group were appropriate to be seen in secondary care. The 2-week wait scheme has so far failed to reduced waiting times for lung cancer. The findings of this study suggest that this is partly due to continued usage of urgent referral routes outside the 2-week wait scheme and secondly due to a large increase in referrals, probably generated by the introduction of the DoH guidelines. Some adjustment to the guidelines may be appropriate to reflect more emphasis on the early performance of a chest X-ray and the use of direct access to other imaging modalities such as CT. Patients referred outside the 2-week wait are disadvantaged and thus practitioners would be wise to refer all their patients through the 2-week wait system. Nature Publishing Group 2005-10-17 2005-09-27 /pmc/articles/PMC2361660/ /pubmed/16189521 http://dx.doi.org/10.1038/sj.bjc.6602798 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Lewis, N R
Le Jeune, I
Baldwin, D R
Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title_full Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title_fullStr Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title_full_unstemmed Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title_short Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
title_sort under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361660/
https://www.ncbi.nlm.nih.gov/pubmed/16189521
http://dx.doi.org/10.1038/sj.bjc.6602798
work_keys_str_mv AT lewisnr underutilisationofthe2weekwaitinitiativeforlungcancerbyprimarycareanditseffectontheurgentreferralpathway
AT lejeunei underutilisationofthe2weekwaitinitiativeforlungcancerbyprimarycareanditseffectontheurgentreferralpathway
AT baldwindr underutilisationofthe2weekwaitinitiativeforlungcancerbyprimarycareanditseffectontheurgentreferralpathway